IP Library Granted Patent US 12,674,136
Granted Patent B2
US 12,674,136 · App. 18/259,611 · Granted Jul 7, 2026

Methods for preparing tumor-infiltrating lymphocytes

Inventors: Jia Li (Shanghai, CN); Jiyan Hou (Shanghai, CN); Zizhen Gong (Shanghai, CN); Yijie Qu (Shanghai, CN); Shichao Qin (Shanghai, CN); Shenchen Wang (Shanghai, CN); Wangqin Shu (Shanghai, CN); Junfeng Wu (Shanghai, CN); Fei Wang (Shanghai, CN); Li Zhang (Shanghai, CN)
Assignee: Shanghai AbelZeta Ltd.
C12N5/0634A61K40/11A61K40/42A61P35/00C12N5/0636C12N5/0638C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/2321C12N2501/73C12N2501/734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,136
App. No.
18/259,611
Filed
Jun 28, 2023
Granted
Jul 7, 2026
Kind
B2
Art Unit
1674
USPC
424/93.71
Abstract

Provided are methods for expanding tumor-infiltrating lymphocytes (TILs), which include co-culturing an initial cell population containing TILs with first feeder cells to obtain a first expanded cell population; and then co-culturing the first expanded cell population with second feeder cells to obtain an expanded TIL population. The methods can quickly produce a large number of TILs from a small tumor sample.

Claims (13)

1 . A method for preparing tumor-infiltrating lymphocytes (TILs) in vitro, the method comprising:

(1) providing an initial cell population containing TILs from a sample, wherein the number of TILs in the initial cell population is n0 wherein n0 ranges from 1,000 to 50,000;

(2) pre-treating the initial cell population, the pretreatment comprising culturing the initial cell population with IL7, IL15 and IL21 for 6 hours to 36 hours, to obtain a pretreated initial cell population, wherein each of IL7, IL15, and IL21 has a concentration ranging from 10 ng/ml to 100 μg/ml;

(3) co-culturing the pretreated initial cell population, with first feeder cells in a first culture medium for a first period of 7 days to 16 days, to obtain a first expanded cell population, wherein the first culture medium comprises (i) one or more cytokines selected from the group consisting of IL2, IL7, IL15, and IL21, and (ii) one or more antibodies selected from the group consisting of an anti-CD3 antibody or fragments thereof, an anti-41BB antibody or fragments thereof, an anti-OX40 antibody or fragments thereof, and an anti-PD-1 antibody or fragments thereof, wherein the number of TILs in the first expanded cell population is n1, wherein n1/n0 ranges from 1000 to 10,000, and n1 is at least 1×10 7 ; and

(4) co-culturing the first expanded cell population with second feeder cells in a second culture medium for a second period of 10 days to 16 days, to obtain an expanded TIL population, wherein the second culture medium comprises one or more antibodies selected from the group consisting of an anti-CD3 antibody or fragments thereof, and an anti-CD28 antibody or fragments thereof, wherein the number of TILs in the expanded TIL population is n2, wherein n2/n1 ranges from 4000 to 10,000, and n2 is at least 1×10 10 .

2 . The method of claim 1 , wherein the sample is a tumor sample.

3 . The method of claim 2 , wherein the tumor sample is from a solid tumor.

4 . The method of claim 3 , wherein the solid tumor is lung cancer, cervical cancer, ovarian cancer, or melanoma.

5 . The method of claim 1 , wherein the sample has a weight ranging from 0.01 g to 0.5 g.

6 . The method of claim 1 , wherein in step (1), the sample is dissociated with a dissociation solution to obtain the initial cell population, wherein the dissociation solution comprises an isotonic solution comprising collagenase II, collagenase IV, DNase, and hyaluronidase.

7 . The method of claim 1 , wherein the second culture medium comprises microbeads coated with one or more antibodies selected from the group consisting of an anti-CD3 antibody or fragments thereof, and an anti-CD28 antibody or fragments thereof.

8 . The method of claim 1 , wherein the first feeder cells and the second feeder cells are antigen presenting cells.

9 . The method of claim 1 , wherein the first feeder cells and the second feeder cells are peripheral blood mononuclear cells (PBMCs).

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67128 FRAME: 44. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 7, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067334/0083 →
CHANGE OF NAME Recorded Apr 16, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067128/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2023
From: LI, JIA; HOU, JIYAN; GONG, ZIZHEN; QU, YIJIE; QIN, SHINCHAO; WANG, SHENCHEN; SHU, WANGQIN; WU, JUNFENG; WANG, FEI; ZHANG, LI
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 065646/0210 →
Priority Claims (1)
CN 202011629408.7 · Dec 31, 2020 · national
Continuity (1)
Related Publication 20240060041A1 · Feb 22, 2024
References Cited (23)
US 10420799B2 · Wardell et al. · 2019 [cited by applicant]
US 20190276802A1 · Simpson-Abelson et al. · 2019 [cited by applicant]
US 20200338125A1 · Bobisse et al. · 2020 [cited by applicant]
CN 103396991A · 2013 [cited by applicant]
CN 110042080A · 2019 [cited by applicant]
CN 110099998A · 2019 [cited by applicant]
CN 110199016A · 2019 [cited by applicant]
CN 111040995A · 2020 [cited by applicant]
CN 110785486A · 2020 [cited by applicant]
CN 111286486A · 2020 [cited by applicant]
CN 111801415A · 2020 [cited by applicant]
JP 2019534030A · 2019 [cited by applicant]
JP 2020515257A · 2020 [cited by applicant]
WO 2018204761A1 · 2018 [cited by applicant]
WO 2019190579A1 · 2019 [cited by applicant]
WO 2019210131A1 · 2019 [cited by applicant]
WO 2020096988A2 · 2020 [cited by applicant]
International Search Report and Written Opinion of PCT/CN2021/142540, mailed Mar. 30, 2022. [cited by applicant]
Baldan et al. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br J Cancer 112, 1510-1518 (2015). [cited by applicant]
Friedman et al. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother. 2011; 34(9):651-661. [cited by applicant]
Lee et al., Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. Oncotarget. 2017; 8(69):113345-113359. [cited by applicant]
Ye et al., CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014, 20(1):44-55. [cited by applicant]
Yunger et al., Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy, Oncolmmunology, (2019) 8(12): e1672494. [cited by applicant]